WO1997038085A3 - Genes amplifies dans des cellules cancereuses - Google Patents

Genes amplifies dans des cellules cancereuses Download PDF

Info

Publication number
WO1997038085A3
WO1997038085A3 PCT/US1997/005930 US9705930W WO9738085A3 WO 1997038085 A3 WO1997038085 A3 WO 1997038085A3 US 9705930 W US9705930 W US 9705930W WO 9738085 A3 WO9738085 A3 WO 9738085A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
cancer
gene
cells
genes
Prior art date
Application number
PCT/US1997/005930
Other languages
English (en)
Other versions
WO1997038085A2 (fr
Inventor
Helene Smith
Ling-Chun Chen
Original Assignee
California Pacific Med Center
Helene Smith
Chen Ling Chun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1996/009286 external-priority patent/WO1996039516A2/fr
Priority claimed from US08/678,280 external-priority patent/US5776683A/en
Application filed by California Pacific Med Center, Helene Smith, Chen Ling Chun filed Critical California Pacific Med Center
Priority to AU24521/97A priority Critical patent/AU2452197A/en
Priority to EP97920293A priority patent/EP0944651A2/fr
Priority to JP9536486A priority patent/JP2000509256A/ja
Publication of WO1997038085A2 publication Critical patent/WO1997038085A2/fr
Publication of WO1997038085A3 publication Critical patent/WO1997038085A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des nouveaux procédés pour détecter des gènes associés au cancer et produire des séquences d'ADNc correspondantes. Lesdits procédés consistent à produire des préparations d'ARN à partir de cellules de régulation et de plusieurs cellules cancéreuses différentes partageant un gène dupliqué ou modifié dans la même région d'un chromosome. Des copies d'ADNc amplifié sont visualisées puis sélectionnées en fonction des différences d'abondance d'ARN entre les préparations. Les étapes de criblages supplémentaires optionnelles consistent à rechercher dans des séries de cellules cancéreuses au moyen de l'ADNc la surabondance d'ARN avec ou sans duplication génique. Les gènes identifiés peuvent être utilisés à leur tour pour mettre au point des matériaux et des techniques de traitement et de diagnostic du cancer sous-jacent. On a identifié quatre nouveaux gènes associés au cancer. Dans environ 60 % des lignées de cellules du cancer du sein testées, l'ARN s'hybridant avec les ADN était sensiblement plus abondant que dans des cellules normales. La plupart des lignées cellulaires présentaient également une duplication du gène correspondant, ce qui semble avoir contribué au fait que le niveau d'ARN dans la cellule est accru. Néanmoins, pour chacun des quatre gènes, certaines cellules présentaient une surabondance sans duplication génique, ce qui semble indiquer que le produit génique est suffisamment important dans le processus cancéreux pour que les cellules utilisent plusieurs mécanismes différents pour amplifier leur expression.
PCT/US1997/005930 1996-04-10 1997-04-09 Genes amplifies dans des cellules cancereuses WO1997038085A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU24521/97A AU2452197A (en) 1996-04-10 1997-04-09 Genes amplified in cancer cells
EP97920293A EP0944651A2 (fr) 1996-04-10 1997-04-09 Genes amplifies dans des cellules cancereuses
JP9536486A JP2000509256A (ja) 1996-04-10 1997-04-09 ガン細胞において増幅される遺伝子

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US1516796P 1996-04-10 1996-04-10
US60/015,167 1996-04-10
USPCT/US96/09286 1996-06-05
PCT/US1996/009286 WO1996039516A2 (fr) 1995-06-05 1996-06-05 Cibles pour le diagnostic et le traitement du cancer du sein
US1920296P 1996-06-06 1996-06-06
US60/019,202 1996-06-06
US08/678,280 1996-07-11
US08/678,280 US5776683A (en) 1996-07-11 1996-07-11 Methods for identifying genes amplified in cancer cells

Publications (2)

Publication Number Publication Date
WO1997038085A2 WO1997038085A2 (fr) 1997-10-16
WO1997038085A3 true WO1997038085A3 (fr) 1998-02-19

Family

ID=27486464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/005930 WO1997038085A2 (fr) 1996-04-10 1997-04-09 Genes amplifies dans des cellules cancereuses

Country Status (4)

Country Link
EP (1) EP0944651A2 (fr)
JP (1) JP2000509256A (fr)
AU (1) AU2452197A (fr)
WO (1) WO1997038085A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170864A1 (en) 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7160985B2 (en) 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
US20030105298A1 (en) 1998-06-16 2003-06-05 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7351543B2 (en) 1998-06-02 2008-04-01 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma
US7319008B2 (en) 1998-06-02 2008-01-15 Genentech, Inc. Nucleic acid underexpressed in melanoma
US7244428B2 (en) 1998-09-10 2007-07-17 Genentech, Inc. PRO1357 antibodies
US7244817B2 (en) 1998-09-10 2007-07-17 Genentech, Inc. Pro1357 polypeptide
US7399828B2 (en) 1998-09-24 2008-07-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7402661B2 (en) 1998-10-06 2008-07-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9827430D0 (en) * 1998-12-11 1999-02-03 Ludwig Inst Cancer Res Differential expression in primary breast cancer
US7465785B2 (en) 1999-03-08 2008-12-16 Genentech, Inc. Polypeptide encoded by a nucleic acid over-expressed in melanoma
US7507404B2 (en) 1999-03-08 2009-03-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7423127B2 (en) 1999-12-09 2008-09-09 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid overexpressed in melanoma
US7300758B2 (en) 1999-12-09 2007-11-27 Genetech, Inc. Nucleic acid underexpressed in esophageal tumor
US7288384B2 (en) 1999-12-09 2007-10-30 Genentech, Inc. Antibodies to polypeptides encoded by a nucleic acid underexpressed in esophageal tumor
US20030018183A1 (en) 2001-12-06 2003-01-23 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7989167B2 (en) * 2006-11-13 2011-08-02 Val-Chum L.P. Method of prognosing and diagnosing hereditary spastic paraplegia, mutant nucleic acid molecules and polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1991002062A2 (fr) * 1989-08-04 1991-02-21 Triton Biosciences, Inc. Domaine externe du c-erbb-2: gp75
WO1992021771A1 (fr) * 1991-06-03 1992-12-10 Triton Diagnostics, Inc. Ectodomaine de recepteur du facteur de croissance epidermique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1991002062A2 (fr) * 1989-08-04 1991-02-21 Triton Biosciences, Inc. Domaine externe du c-erbb-2: gp75
WO1992021771A1 (fr) * 1991-06-03 1992-12-10 Triton Diagnostics, Inc. Ectodomaine de recepteur du facteur de croissance epidermique

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ADNANE J ET AL: "BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers.", ONCOGENE, APR 1991, 6 (4) P659-63, ENGLAND, XP000607852 *
BERNS EM ET AL: "SPORADIC AMPLIFICATION OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR GENE IN HUMAN BREAST TUMORS", CANCER RES;52(4):1036-9 1992, XP002037748 *
BIECHE I ET AL: "LOSS AND GAIN OF DISTINCT REGIONS OF CHROMOSOME 1Q IN PRIMARY BREAST-CANCER", CLINICAL CANCER RESEARCH, 1995, 1, 123-127, XP000609027 *
CHEN Z ET AL: "Differential expression of human tissue factor in normal mammary epithelial cells and in carcinomas.", MOL MED, JAN 1995, 1 (2) P153-60, UNITED STATES, XP000607858 *
EMBL database ion number D83780 16-03- Nomura n. Human mRNA for KIA *
EMBL database ion number H15342 Hillie t al. The Washu-Me T project 03-07-95 *
LIANG P ET AL: "DIFFERENTIAL DISPLAY OF EUKARYOTIC MESSENGER RNA BY MEANS OF THE POLYMERASE CHAIN REACTION", SCIENCE, vol. 257, no. 5072, 14 August 1992 (1992-08-14), pages 967 - 971, XP000508268 *
NAGASE T ET AL: "Prediction of the coding sequences of unidentified human genes. V. The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by analysis of cDNA clones from human cell line KG-1.", DNA RES, FEB 29 1996, 3 (1) P17-24, JAPAN, XP002037754 *
SLAMON DJ ET AL: "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.", SCIENCE, MAY 12 1989, 244 (4905) P707-12, UNITED STATES, XP002019974 *
WATSON MA ET AL: "Isolation of differentially expressed sequence tags from human breast cancer.", CANCER RES, SEP 1 1994, 54 (17) P4598-602, UNITED STATES, XP002019977 *

Also Published As

Publication number Publication date
JP2000509256A (ja) 2000-07-25
AU2452197A (en) 1997-10-29
WO1997038085A2 (fr) 1997-10-16
EP0944651A2 (fr) 1999-09-29

Similar Documents

Publication Publication Date Title
WO1997038085A3 (fr) Genes amplifies dans des cellules cancereuses
WO1996039516A3 (fr) Cibles pour le diagnostic et le traitement du cancer du sein
De Crombrugghe et al. Regulation of lac mRNA synthesis in a soluble cell-free system
Boyce et al. Release of ultraviolet light-induced thymine dimers from DNA in E. coli K-12
Arndt et al. A suppressor of a HIS4 transcriptional defect encodes a protein with homology to the catalytic subunit of protein phosphatases
Wells et al. Telomere-related sequences at interstitial sites in the human genome
Jablonka et al. DNA hypomethylation causes an increase in DNase-I sensitivity and an advance in the time of replication of the entire inactive X chromosome
Toyoda et al. Regulation of glutathione peroxidase mRNA level by dietary selenium manipulation
Travers et al. Oestrogen-induced expression of oncogenes in the immature rat uterus
Goshorn et al. Genetic analysis of prototrophic natural variants of Candida albicans.
EE9700255A (et) Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ß retseptori antikehad kasvajavastaste agensitena
Roth et al. Transfer RNA and the control of the histidine operon
PT1003865E (pt) Mutação no gene conexina 26 responsável pela surdez prélingual não sindromática e método de detecção
Tatematsu et al. Precocious differentiation of immature chief cells in fundic mucosa of infant rats induced by hydrocortisone
EP0045573A3 (fr) Segment eucaryotique à replication autonome
Schäfer et al. Mitochondrial genes in Neurospora: A single cistron for ribosomal RNA
Brazill et al. Changing levels of UV light and carcinogen-induced unscheduled DNA synthesis in mouse oocytes during meiotic maturation
EP2281892A3 (fr) Procédé de préparer des polypeptides dans de cellules Trichoderma avec des déficiences respiratoires
Vielmetter et al. Genetic evidence for transfer of a single DNA strand during bacterial conjugation
Ross et al. Changes in isozyme patterns between monokaryons and dikaryons of a bipolar Coprinus
MX9805299A (es) Novedosos polinucleotidos panc1a y panc1b asociados con cancer pancreatico.
IL126257A (en) Immuno-magnetic cell separation for use in identification of genes associated with site-preferenced cancer methastasis formation
WO2000009655A3 (fr) Genes amplifies dans des cellules cancereuses
Farrar et al. Interactions of photoactive DNAs with terminal deoxynucleotidyl transferase: identification of peptides in the DNA binding domain
Sellem et al. Activation of a silent gene is accompanied by its demethylation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT.BUL.44/97, UNDER INID(81)"DESIGNATED STATES",ADD"BA,CU,GH,LC,YU"

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT.BUL.44/97, UNDER INID(30)"PRIORITY DATA",REPLACE"960409"BY"960410"AND"960710"BY"960711"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 332691

Country of ref document: NZ

Ref document number: 1997920293

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997920293

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997920293

Country of ref document: EP